Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series.

Background: National treatment guidelines recommend glucagon-like peptide receptor agonists (GLP-1 RAs) as add-on therapy to oral agents. However, GLP-1 RAs in combination with dipeptidyl peptidase-4 (DPP-4) inhibitors is not recommended due to a lack of evidence.

Objective: This case series aims to describe the efficacy and safety of once-weekly GLP-1 RAs administered concomitantly with DPP-4 inhibitors in patients with type 2 diabetes.

77Se NMR spectroscopic, DFT MO, and VBT investigations of the reversible dissociation of solid (Se6I2)[AsF6]2.2SO2 in Liquid SO2 to solutions containing 1,4-Se6I2(2+) in equilibrium with Se(n)2+ (n = 4, 8, 10) and seven binary selenium iodine cations: preliminary evidence for 1,1,4,4-Se4Br4(2+) and cyclo-Se7Br+.

The composition of a complex equilibrium mixture formed upon dissolution of (Se(6)I(2))[AsF(6)](2).2SO(2) in SO(2)(l) was studied by (77)Se NMR spectroscopy at -70 degrees C with both natural-abundance and enriched (77)Se-isotope samples (enrichment 92%). Both the natural-abundance and enriched NMR spectra showed the presence of previously known cations 1,4-Se(6)I(2)(2+), SeI(3)(+), 1,1,4,4-Se(4)I(4)(2+), Se(10)(2+), Se(8)(2+), and Se(4)(2+).